Al-Ibraheem Akram, Abdlkadir Ahmed Saad, Sweedat Deya' Aldeen, Maus Stephan, Al-Rasheed Ula, Salah Samer, Khriesh Fadi, Juaidi Diyaa, Abu Dayek Dina, Istatieh Feras, Anwar Farah, Asrawi Aisha, Abufara Alaa, Al-Rwashdeh Mohammad, Abu-Hijlih Ramiz, Sharaf Baha', Ghanem Rami, Abdel-Razeq Hikmat, Mansour Asem
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
School of Medicine, University of Jordan, Al-Jubeiha, Amman 11942, Jordan.
Cancers (Basel). 2024 May 23;16(11):1974. doi: 10.3390/cancers16111974.
The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities. Approximately half of the cases (n = 26) demonstrated an initial partial response to PSMA radioligand therapy. Moreover, roughly one-fourth of the patients (n = 13) exhibited a sustained satisfactory biochemical response, which qualified them to receive a total of six PSMA radioligand therapy cycles and maintain continued follow-up for additional treatment cycles. This was reflected by an adequate prostate-specific antigen (PSA) decline and a concomitant partial response evident on [Ga]Ga-PSMA positron emission tomography/computed tomography imaging. A minority of patients (n= 18; 34%) experienced side effects. Generally, these were low-grade and self-limiting toxicities. This study endorses previous research evidence about PSMA radioligand therapy's safety and efficacy. It also provides the first clinical insight from patients of Arab ethnicity. This should facilitate and promote further evidence, both regionally and internationally.
这项回顾性研究的目的是评估两种发射β射线的前列腺特异性膜抗原（PSMA）放射性配体，即[镥]镥和[铽161]铽，在接受过大量治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中的有效性和安全性。在约旦安曼的一家专业癌症护理中心，对53例患者总共进行了148个周期的发射β射线的PSMA放射性配体治疗。在所有先前治疗方式均用尽后提供了这种治疗。大约一半的病例（n = 26）对PSMA放射性配体治疗表现出初始部分反应。此外，大约四分之一的患者（n = 13）表现出持续的令人满意的生化反应，这使他们有资格总共接受六个周期的PSMA放射性配体治疗，并持续接受后续的额外治疗周期随访。这表现为前列腺特异性抗原（PSA）充分下降，以及在[镓]镓-PSMA正电子发射断层扫描/计算机断层扫描成像上明显出现的伴随部分反应。少数患者（n = 18；34%）出现了副作用。总体而言，这些都是低级别且自限性的毒性反应。本研究认可了先前关于PSMA放射性配体治疗安全性和有效性的研究证据。它还提供了来自阿拉伯族裔患者的首个临床见解。这应有助于并促进区域和国际上的进一步循证研究。
